Effect of Nintedanib on Quantitative CT in Patients With Progressive Pulmonary Fibrosis: Results from the INBUILD Trial

作者
ANAND DEVARAJ,Carina Ittrich,Peter M. George,Eric S. White,Jonathan Gerald Goldin,Olivier Joly,Susanne Stowasser,Frank Risse
出处
期刊:American Journal of Respiratory and Critical Care Medicine [American Thoracic Society]
卷期号:211 (Supplement_1): A7678-A7678 被引量:2
标识
DOI:10.1164/ajrccm.2025.211.abstracts.a7678
摘要

Abstract Rationale: In the placebo-controlled INBUILD trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks compared with placebo in subjects with progressive pulmonary fibrosis (PPF). We used data from a standardized non-contrast high-resolution chest computed tomography (HRCT) sub-study to compare two separate quantitative imaging analysis methods to assess the effects of nintedanib on disease progression. Methods: Subjects had a fibrosing ILD other than idiopathic pulmonary fibrosis and an extent of fibrosis on HRCT >10%. HRCT was acquired at screening/baseline and at weeks 24 and 52 in subjects who consented for the optional HRCT sub-study. We analyzed quantitative lung fibrosis and ILD scores (QLF/QILD) using an established quantitative CT method, and total disease extent (TDE) and weighted reticulovascular score (WRVS) using Brainomix e-Lung. Analyses were based on a linear mixed model for repeated measures for change from baseline in log10 transformed values. Estimates for group differences between nintedanib and placebo were back transformed to original scale. Results: Of 474 subjects recruited to the sub-study, 403 had QLF/QILD scores and 371 had e-Lung scores on baseline CT. Compared with baseline CT, both QILD score and e-Lung TDE demonstrated a significant reduction in extent of lung involvement in nintedanib vs. placebo groups at week 24 (-2.35%, p=0.0045 and -1.81%, p=0.0004, respectively) and at week 52 (-2.49%, p=0.0040 and -1.54%, p=0.0110, respectively). Whereas e-Lung WRVS demonstrated a significant difference in favor of nintedanib at week 24 (-0.71%, p=0.0204) and a numerical difference at week 52 (-0.54%, p=0.1787), QLF showed a significant difference of -1.30% (p=0.0152) in favor of nintedanib at week 52 and a numerical difference at week 24 (-0.87%, p=0.0986) (Table). Conclusion: Quantitative CT as assessed by QILD and e-Lung TDE demonstrated a beneficial effect of nintedanib on lung structure starting at week 24 and persisting through to week 52, further corroborating a slowing of disease progression in patients with PPF.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dianeil完成签到,获得积分10
7秒前
王不凡完成签到 ,获得积分10
9秒前
LWJ完成签到 ,获得积分10
9秒前
竹舍翁暮雨君完成签到 ,获得积分10
12秒前
机智的孤兰完成签到 ,获得积分10
12秒前
拼搏忆文完成签到,获得积分10
15秒前
康康舞曲完成签到 ,获得积分10
16秒前
XU博士完成签到,获得积分10
17秒前
轻歌水越完成签到 ,获得积分10
18秒前
风趣朝雪完成签到,获得积分10
19秒前
Robin完成签到 ,获得积分10
22秒前
一瓣橘子完成签到,获得积分10
23秒前
kk完成签到,获得积分10
27秒前
Fan完成签到 ,获得积分0
28秒前
蔡勇强完成签到 ,获得积分10
31秒前
bo完成签到 ,获得积分0
32秒前
lpp完成签到 ,获得积分10
33秒前
Heby完成签到 ,获得积分10
33秒前
小山己几完成签到,获得积分10
38秒前
吉吉完成签到,获得积分10
38秒前
望向天空的鱼完成签到 ,获得积分10
39秒前
詹姆斯哈登完成签到,获得积分0
40秒前
高贵的鸿涛完成签到,获得积分10
43秒前
凡凡完成签到,获得积分10
44秒前
三羧酸循环完成签到,获得积分10
44秒前
goy完成签到,获得积分10
45秒前
Alvin完成签到 ,获得积分10
45秒前
一叶知秋完成签到,获得积分10
45秒前
俏皮冰露完成签到,获得积分10
46秒前
戴肉肉完成签到 ,获得积分10
46秒前
yoooooooo完成签到,获得积分10
47秒前
猫猫豆包完成签到 ,获得积分10
47秒前
还在学习完成签到 ,获得积分10
48秒前
悟空完成签到,获得积分10
51秒前
狮山教授发布了新的文献求助10
51秒前
穿山的百足公主完成签到 ,获得积分10
52秒前
粗心的书竹完成签到,获得积分10
54秒前
Defotls完成签到 ,获得积分10
56秒前
醉熏的复天完成签到,获得积分10
56秒前
木子子子完成签到 ,获得积分10
57秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180053
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808682
捐赠科研通 7776054
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557425
邀请新用户注册赠送积分活动 2479012